Caribou Biosciences/CRBU

$8.14

-1.45%
-
1D1W1MYTD1YMAX

About Caribou Biosciences

Caribou Biosciences, Inc. is a clinical-stage genome-editing biopharmaceutical company. The Company is developing transformative clustered regularly interspaced short palindromic repeats (CRISPR) therapies for patients with devastating diseases. The Company’s CRISPR platform, CRISPR hybrid RNA-DNA (chRDNA), enables superior genome-editing precision to develop cell therapies that are specifically engineered for enhanced persistence. It is advancing a pipeline of allogeneic, or off-the-shelf, chimeric antigen receptor (CAR)-T (CAR-T) and CAR-natural killer (CAR-NK) cell therapies for the treatment of patients with hematologic malignancies and solid tumors. The Company’s lead product candidate, CB-010, is a clinical-stage allogeneic anti-CD19 CAR-T cell therapy with programmed cell death protein 1 (PD-1) removed from the CAR-T cell surface by a genome-edited knockout of the PDCDI gene. The Company’s product candidate also includes CB-011, CB-012 and CB-020.

Ticker

CRBU

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Rachel Haurwitz

Employees

137

Headquarters

Berkeley, United States

CRBU Metrics

BasicAdvanced
$656.16M
Market cap
-
P/E ratio
-$1.50
EPS
-
Beta
-
Dividend rate

What the Analysts think about CRBU

Analyst Ratings

Majority rating from 9 analysts.
Buy

Price Targets

Average projection from 8 analysts.
170.27% upside
High $30.00
Low $13.00
$8.14
Current price
$22.00
Average price target

CRBU Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-42.37% profit margin
QuarterlyAnnual
Q3 23
QoQ growth
Revenue
$23.6M
537.84%
Net income
$-10M
-66.1%
Profit margin
-42.37%
-94.69%

CRBU Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 71.17%
QuarterlyAnnual
Q4 22
Q1 23
Q2 23
Q3 23
Q4 23
Actual
-$0.44
-$0.46
-$0.48
-$0.12
-
Expected
-$0.46
-$0.49
-$0.49
-$0.42
-$0.37
Surprise
-4.66%
-5.58%
-3%
-71.17%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

Buy or sell Caribou Biosciences stock

Buy or sell Caribou Biosciences stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing